Alto Neuroscience
ANRO
23.17
-0.35
-1.49%
Alto Neuroscience
US · ANRO
#3301 by market cap
Listed 2024
23.17
-0.35
-1.49%
Live - 5344 symbols - heartbeat 530s ago
· 2026-10-08 10:00
Pre-market
23.24
-1.19%
After-hours
23.97
+1.92%
- Market cap
- 909.24M
- P/E (TTM)i
- -9.99
- P/Bi
- 4.15
- EPSi
- -2.19
- Div yieldi
- 0.00%
- 52W posi
- 56%
Reader sentiment
Are you bullish or bearish on ANRO?
Anonymous reader poll. Unscientific, not investment advice.
About Alto Neuroscience
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.
- Founded
- 2019
- CEO
- Dr. Amit Etkin, M.D.,PhD
- Employees
- 68
- Headquarters
- Mountain View, California, United States of America
- Fiscal year end
- 12-31
- Website
- altoneuroscience.com
Company profile
- Exchange
- US
- Symbol
- ANRO
- Market-cap rank
- #3301
- Listing date
- 2024-02-02
- Market cap
- 909.24M
- Float cap
- 685.70M
- Shares out
- 39.24M
- Float shares
- 29.59M
Sectors & themes
Quote time 2026-10-08 10:00:09 · For reference only, not investment advice and not tailored to your situation.